Brain Correlates of Suicide Attempt in 18,925 Participants Across 18 International Cohorts

Grants

Funding Acknowledgements

The work reported here was supported in part by many public and private agencies across the world. Core funding for ENIGMA was provided by the National Institutes of Health (NIH) Big Data to Knowledge (BD2K) program (Consortium Grant No. U54 EB020403 [to PMT]), the University Medical Center Gottingen and the German Federal Ministry of Education and Research (Bundesministerium fuer Bildung und Forschung, BMBF: 01 ZX 1507, ``PreNeSt -e:Med'' [to AFFDIS]), as well by support to the BiDirect study (BMBF; Grant Nos. FKZ-01ER0816 and FKZ-01ER1506), the ETPB study at the NIH (funded by the National Institute of Mental Health [NIMH] Intramural Program), the FOR2107 study (German Research Foundation: Grant Nos. Ki588/14-1 and Ki588/14-2 [to TK]), the IMH Singapore cohort (National Healthcare Group Research: Grant No. SIG/15012 [to KS]), the LOND study (supported in part by the Biomedical Research Centre, South London, and Maudsley NHS Foundation Trust, London, United Kingdom), the Stanford study (supported in part by the NIMH Grant R37-MH101495 [to IHG]), the Melbourne study (Australia's National Health and Medical Research Council [NHMRC] Project Grants 1064643 [to principal investigator, BJH] and 1024570 [to principal investigator, CGD]), the QTIM study (National Institute of Child Health and Human Development Grant No. R01HD050735 and NHMRC Australia Grant Nos. 486682 and 1009064 [to principal investigator, MJW]), the Pharmo study in Amsterdam (faculty resources of the Academic Medical Center, University of Amsterdam, and 11.32050.26 ERA-NET PRIOMEDCHILD FP 6 [EU]), and the UCSF study (funded in part by the NIMH Grant Nos. R01MH085734 and K01MH117442 [to TTY and TCH]; National Center for Complementary and Integrative Health [NCCIH Grant No. 1R61AT009864]; and the American Foundation for Suicide Prevention [AFSP]). The Edinburgh group is funded by a Wellcome Trust Strategic Award "Stratifying Resilience and Depression Longitudinally" (STRADL) (Reference 104036/Z/14/Z [to AMM]). The SHIP cohort is part of the Community Medicine Research Network of the University Medicine Greifswald, which is supported by the German Federal State of Mecklenburg-West Pomerania. This work was also supported by a UQ Research Training Scholarship from The University of Queensland (UQ [to AIC]), the NHMRC and Australian Research Council (ARC) through a Research Fellowship (Grant No. APP1102821 [to MER]), NHMRC Career Development Fellowships (Grant Nos. 1124472 and 1061757, respectively [to BJH and CGD]), NHMRC (Grant Nos. APP1103623, APP1158127, and APP1172917 [to SEM]), NCCIH (Grant No. 1R61AT009864 [to TTY]), and the NIMH of the NIH (U.S.) under Award Number R01-MH117601 (to LS and NJ).This project used data from the UK Biobank under application number 25331.HJG has received travel grants and speaker's honoraria from Fresenius Medical Care, Neuraxpharm, Servier, and Janssen Cilag as well as research funding from Fresenius Medical Care. CAZ is a full-time U.S. government employee. He is listed as a coinventor on a patent for the use of ketamine and its metabolites in major depression and suicidal ideation. CAZ has assigned his patent rights to the U.S. government but will share a percentage of any royalties that may be received by the government. NJ and PMT are MPI of a research-related grant from Biogen, Inc., for work unrelated to this manuscript. IBH is funded by NHMRC Fellowship (2013-2017 and 2018-2022). He is the Chief Scientific Advisor to, and a 5% equity shareholder in, InnoWell Pty Ltd. InnoWell was formed by the University of Sydney (45% equity) and PwC (Australia; 45% equity) to deliver the $30 M Australian Government-funded Project Synergy (2017-2020). All other authors report no biomedical financial interests or potential conflicts of interest.